Search research articles
Contact Us
Filters
Showing results (61-70 of 137) with videos related to
Page
of 14
Sort By:
Clinical and Translational Radiation Oncology
|
September 23, 2024
Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma
Sydney A Keatts, Aya F Salem, David M Swanson, et al.
Oncoimmunology
|
December 21, 2023
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases
Pankti Reid, Sabina Sandigursky, Juhee Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
ESMO Open
|
February 2, 2018
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
Isabella C Glitza, Michelle Rohlfs, Nandita Guha-Thakurta, et al.
Journal for Immunotherapy of Cancer
|
April 21, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Nizar M Tannir, Daniel C Cho, Adi Diab, et al.
European Urology
|
June 1, 2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, et al.
Nature Communications
|
November 14, 2017
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
Manisha Singh, Christina Vianden, Mark J Cantwell, et al.
Future Oncology (London, England)
|
January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Adi Diab, Omid Hamid, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2018
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model
Sharareh Niknam, Hampartsoum B Barsoumian, Jonathan E Schoenhals, et al.
Page
of 14
Search research articles
Search
Showing results (61-70 of 137) with videos related to
Sort By:
Page
of 14
Clinical and Translational Radiation Oncology
|
September 23, 2024
Durable local control with hypofractionated radiation therapy for unresectable or metastatic melanoma
Sydney A Keatts, Aya F Salem, David M Swanson, et al.
Oncoimmunology
|
December 21, 2023
Safety and effectiveness of combination versus monotherapy with immune checkpoint inhibitors in patients with preexisting autoimmune diseases
Pankti Reid, Sabina Sandigursky, Juhee Song, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
July 2, 2021
Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules
Georgina V Long, Caroline Robert, Marcus O Butler, et al.
ESMO Open
|
February 2, 2018
Retrospective review of metastatic melanoma patients with leptomeningeal disease treated with intrathecal interleukin-2
Isabella C Glitza, Michelle Rohlfs, Nandita Guha-Thakurta, et al.
Journal for Immunotherapy of Cancer
|
April 21, 2022
Bempegaldesleukin plus nivolumab in first-line renal cell carcinoma: results from the PIVOT-02 study
Nizar M Tannir, Daniel C Cho, Adi Diab, et al.
European Urology
|
June 1, 2022
Bempegaldesleukin plus Nivolumab in First-line Metastatic Urothelial Carcinoma: Results from PIVOT-02
Arlene O Siefker-Radtke, Daniel C Cho, Adi Diab, et al.
Nature Communications
|
November 14, 2017
Intratumoral CD40 activation and checkpoint blockade induces T cell-mediated eradication of melanoma in the brain
Manisha Singh, Christina Vianden, Mark J Cantwell, et al.
Future Oncology (London, England)
|
January 25, 2022
PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence
Alexander Mm Eggermont, Paolo A Ascierto, Nikhil I Khushalani, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
October 7, 2021
A Phase I, Open-Label, Dose-Escalation Study of the OX40 Agonist Ivuxolimab in Patients with Locally Advanced or Metastatic Cancers
Adi Diab, Omid Hamid, John A Thompson, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
May 23, 2018
Radiation Followed by OX40 Stimulation Drives Local and Abscopal Antitumor Effects in an Anti-PD1-Resistant Lung Tumor Model
Sharareh Niknam, Hampartsoum B Barsoumian, Jonathan E Schoenhals, et al.
Page
of 14